Is human cell therapy research caught in a mousetrap?

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 224-227

  Barrett, John A ^a   Joseph Melenhorst, J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; HLA A2 ANTIGEN; INTERLEUKIN 11; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CELL THERAPY; DNA POLYMORPHISM; EXPERIMENTAL TRANSPLANTATION; GENE THERAPY; GENETIC TRANSDUCTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOTHERAPY; NONHUMAN; NOTE; PUBLICATION; REGULATORY T LYMPHOCYTE;

EID: 79551629547     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.304     Document Type: Note

References (41)

1. Brown, SD and Hancock, JM (2006). The mouse genome. Genome Dyn 2: 33-45.
2. Little, MT and Storb, R (2002). History of haematopoietic stem-cell transplantation. Nat Rev Cancer 2: 231-238.
3. Bedell, MA, Largaespada, DA, Jenkins, NA and Copeland NG (1997). Mouse models of human disease. Part II: recent progress and future directions. Genes Dev 11: 11-43.
4. Shlomchik, WD (2007). Graft-versus-host disease. Nat Rev Immunol 7: 340-352.
5. Negrin, RS and Contag, CH (2006). In vivo imaging using bioluminescence: a tool for probing graftversus- host disease. Nat Rev Immunol 6: 484-490.
6. Reddy, P, Negrin, R and Hill, GR (2008). Mouse models of bone marrow transplantation. Biol Blood Marrow Transplant 14(1 suppl. 1): 129-135.
7. Mestas, J and Hughes, CC (2004). Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731-2738.
8. Ziegler, SF (2006). FOXP3: of mice and men. Annu Rev Immunol 24: 209-226.
9. Bernardo, ME, Locatelli, F and Fibbe, WE (2009). Mesenchymal stromal cells. Ann NY Acad Sci 1176: 101-117.
10. Koo, GC, Hasan, A and O'Reilly, RJ (2009). Use of humanized severe combined immunodeficient mice for human vaccine development. Expert Rev Vaccines 8: 113-120.
11. van Bekkum, DW, Roodenburg, J, Heidt, PJ and van der Waaij, D (1974). Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 52: 401-404.
12. Heit, H, Heit, W, Kohne, E, Fliedner, TM and Hughes, P (1977). Allogeneic bone marrow transplantation in conventional mice: I. Effect of antibiotic therapy on long term survival of allogeneic chimeras. Blut 35: 143-153.
13. van Bekkum, DW and Knaan, S (1977). Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst 58: 787-790.
14. Liu, KL, Herbrecht, R, Lioure, B, Jaulhac, B, Maloisel, F, Dufour, P et al. (1995). Effects of bacterial nasooropharyngeal colonisation on acute graft-versushost disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 15: 65-69.
15. Heidt, PJ and Vossen, JM (1992). Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation. J Med 23: 161-173.
16. Powell, JD, Fitzhugh, C, Kang, EM, Hsieh, M, Schwartz, RH and Tisdale, JF (2005). Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism. Transplantation 80: 1541-1545.
17. Hsieh, MM, Kang, EM, Fitzhugh, CD, Link, MB, Bolan, CD, Kurlander, R et al. (2009). Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 361: 2309-2317.
18. Rosenberg, SA (2010). Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther 18: 1744-1745.
19. Teshima, T, Hill, GR, Pan, L, Brinson, YS, van den Brink, MR, Cooke, KR et al. (1999). IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 104: 317-325.
20. Antin, JH, Lee, SJ, Neuberg, D, Alyea, E, Soiffer, RJ, Sonis, S et al. (2002). A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 29: 373-377.
21. Weaver, TA, Charafeddine, AH and Kirk, AD (2008). Costimulation blockade: towards clinical application. Front Biosci 13: 2120-2139.
22. Malkovsky, M, Medawar, PB, Thatcher, DR, Toy, J, Hunt, R, Rayfield, LS et al. (1985). Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate. Proc Natl Acad Sci USA 82: 536-538.
23. Malkovsky, M, Brenner, MK, Hunt, R, Rastan, S, Dore, C, Brown, S et al. (1986). T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol 103: 476-480.
24. Sykes, M, Romick, ML, Hoyles, KA and Sachs, DH (1990). In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med 171: 645-658.
25. Sykes, M, Romick, ML and Sachs, DH (1990). Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 87: 5633-5637.
26. Sykes, M, Abraham, VS, Harty, MW and Pearson, DA (1993). IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 150: 197-205.
27. Sykes, M, Harty, MW, Szot, GL and Pearson, DA (1994). Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versusleukemia effects. Blood 83: 2560-2569.
28. Sykes, M, Harty, MW and Pearson, DA (1994). Strain dependence of interleukin-2-induced graft-versus-host disease protection: evidence that interleukin-2 inhibits selected CD4 functions. J Immunother Emphasis Tumor Immunol 15: 11-21.
29. Rosenberg, SA (1988). Cancer therapy with interleukin- 2: immunologic manipulations can mediate the regression of cancer in humans. J Clin Oncol 6: 403-406.
30. Zorn, E, Mohseni, M, Kim, H, Porcheray, F, Lynch, A, Bellucci, R, et al. (2009). Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15: 382-388.
31. Suntharalingam, G, Perry, MR, Ward, S, Brett, SJ, Castello-Cortes, A, Brunner, MD et al. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028.
32. Davis, MM (2008). A prescription for human immunology. Immunity 29: 835-838.
33. Herzog, RW (2010). Gene therapy for SCID-X1: round 2. Mol Ther 18: 1891.
34. Williams, DA, Thrasher, AJ and Baum, C (2010). Transatlantic consortium spotlights need for changes in gene therapy trials. Mol Ther 18: 1892.
35. Holtappels, R, Bohm, V, Podlech, J and Reddehase, MJ (2008). CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model. Med Microbiol Immunol 197: 125-134.
36. Riddell, SR, Watanabe, KS, Goodrich, JM, Li, CR, Agha, ME and Greenberg, PD (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
37. Walter, EA, Greenberg, PD, Gilbert, MJ, Finch, RJ, Watanabe, KS, Thomas, ED, et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
38. Rooney, CM, Smith, CA, Ng, CY, Loftin, S, Li, C, Krance, RA et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345: 9-13.
39. Lacerda, JF, Ladanyi, M, Louie, DC, Fernandez, JM, Papadopoulos, EB, O'Reilly, RJ (1996). Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J Exp Med 183: 1215-1228.
40. Buchsbaum, RJ, Fabry, JA and Lieberman, J (1996). EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice. Immunol Lett 52: 145-52.
41. Merlo, A, Turrini, R, Dolcetti, R, Zanovello, P, Amadori, A and Rosato, A. (2008). Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin Biol Ther 8: 1265-1294.